This standard specifies the requirements for expected performance, design characteristics, design evaluation, sterilization, product packaging, product labeling and information provided by the manufacturer to determine the safety of viscoelastic agents. This standard applies to ophthalmic viscoelastic agents (hereinafter referred to as "viscoelastic agents"), which are substances with viscous and/or viscoelastic properties used in human anterior chamber surgery. Viscoelastic agents are used to create and maintain anterior chamber space to protect intraocular tissues and facilitate operation during surgery.
YY 0861-2011 Referenced Document
GB/T 16886.1 Biological evaluation of medical devices—Part 1: Evaluation and testing within a risk management process*, 2022-04-15 Update
GB/T 16886.10 Biological evaluation of medical devices—Part 10: Tests for irritation and skin sensitization*, 2017-12-29 Update
GB/T 16886.16 Biological evaluation of medical devices—Part 16: Toxicokinetic study design for degradation products and leachables*, 2021-11-26 Update
GB/T 16886.2 Biological evaluation of medical devices.Part 2: Animal welfare requirements
GB/T 16886.5 Biological Evaluation of Medical Devices Part 5: In Vitro Cytotoxicity Tests*, 2018-07-01 Update
GB/T 16886.6 Biological evaluation of medical devices—Part 6:Tests for local effects after implantation*, 2022-04-15 Update
GB/T 16886.9 Biological Evaluation of Medical Devices Part 9: Qualitative and Quantitative Framework for Potential Degradation Products*, 2022-12-30 Update
GB/T 19633 Packaging for terminally sterilized medical devices
YY/T 0297 Clinical investigation of medical devices
YY/T 0316 Medical devices.Application of risk management to medical devices*, 2016-01-26 Update
YY/T 0466.1 Symbols for medical devices used for information provided by manufacturers Part 1: General requirements*, 2023-09-05 Update
YY/T 0640 General requirements for passive surgical implants*, 2016-07-29 Update
YY/T 0771.2-2009 Medical devices utilizing animal tissues and their derivatives.Part 2:Controls on sourcing,collection and handling
YY/T 0771.3-2009 Medical devices utilizing animal tissues and their derivatftives Part 3: Validation of the elimination and/or inactivation of viruses and Transmissible Spongiform Encephalopathy(TSE) agents